Allen Lutz, an analyst from Bank of America Securities, reiterated the Buy rating on Envista Holdings (NVST – Research Report). The associated price target remains the same with $26.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Allen Lutz has given his Buy rating due to a combination of factors including Envista Holdings’ strong performance in the fourth quarter, where growth in consumables, implants, and aligners helped offset challenges in other areas. The company is on a positive trajectory for margin expansion, supported by various growth drivers expected to materialize by FY25. Envista is actively working on improving its implant business, enhancing Spark margins with double-digit growth, and implementing cost management strategies that are projected to provide a significant earnings per share benefit.
Additionally, the company is optimizing its cash flow through a share repurchase program, which is expected to further support earnings growth. The guidance issued by the company is viewed as conservative, and there is a positive outlook on the management’s efforts to stimulate growth and optimize the balance sheet, positioning Envista for potential earnings upgrades. As a result of these factors, Allen Lutz maintains a Buy rating and sets a price objective at $26, reflecting confidence in the company’s strategic initiatives and future performance.
Lutz covers the Healthcare sector, focusing on stocks such as Hims & Hers Health, Cardinal Health, and DENTSPLY SIRONA. According to TipRanks, Lutz has an average return of 10.8% and a 67.05% success rate on recommended stocks.